Can RAD1901 Be Used in Breast Cancer Patients with ESR1 Mutations? - 102164

Spotlight
Video

Can RAD1901 Be Used in Breast Cancer Patients with ESR1 Mutations?

Loading........
Description: Aditya Bardia, MD, MPH of Harvard Medical School and Massachusetts General Hospital Cancer Center discusses common questions he's asked regarding his study on the use of elacestrant (RAD1901) for ER+ advanced breast cancer. This was recorded at the 2017 ASCO Annual Meeting in Chicago, IL.

Abstract 1014: Evaluation of RAD1901, a novel investigational, selective estrogen receptor degrader (SERD), for the treatment of ER-positive (ER+) advanced breast cancer
Shared By : AnnualMeeting2017
Posted on : 06/12/17
Added : 8 months ago
Category : Breast Cancer



Recommended

Nothing found.

More From AnnualMeeting2017

Nothing found.